Skip to main content
S&P 5007,664.14+0.95%DOW52,587.23+1.00%NASDAQ26,367.46+1.10%BTC$76,987.00-0.31%ETH$2,536.62+2.82%GOLD$4,388.70-0.42%OIL$100.38-2.05%
Smart Investors Daily
RE

NASDAQ · RENB

Lunai Bioworks Inc.

Healthcare · Biotechnology

$1.42

Up+$0.00 (+0.00%)

Updated Sep 11, 2026, 6:57 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
32.92M
P/E ratio
-0.24
Dividend yield
0.00%
52-week range
— – —
Volume
808.78K
Avg. volume
218.51K

Price performance

RENB price history

1M range · 0 trading sessions · Daily adjusted prices

RENB does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest RENB news

The latest Smart Investors Daily articles mentioning RENB.

Stock researchCompany · Overview

RENB research

Overview

Company profile and research snapshot.

Company profile

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

accessnewswire.com · Sep 25, 2025

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

NEW YORK CITY, NEW YORK / ACCESS Newswire / September 25, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery company and parent of wholly owned subsidiary BioSymetrics, today announced advancement of its biomarker discovery preclinical program in Parkinson's Disease. The initiative leverages BioSymetrics' proprietary Augusta Platform to unlock novel treatment pathways in one of the world's fastest-growing neurological markets.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By